close
$50 million in first close of new advanced therapies fund
News

$50 million in first close of new advanced therapies fund

$50 million in first close of new advanced therapies fund, 4BIO Ventures II

4BIO Capital, an international venture capital firm focused solely on the advanced therapies sector, has completed the first close of its second venture fund, 4BIO Ventures II. Over $50 million of capital has been committed from family offices and institutional investors. The group is targeting $150 million for the final close by the second half of 2020.
4BIO Ventures II will invest in 8 to 12 private companies developing advanced therapies – such as cell and gene therapy, RNA-based therapy, targeted therapies, and the microbiome – in areas of high unmet need. The objective is to build, support and grow early stage companies with the ultimate goal of ensuring sustainable access to these potentially curative therapies for all patients. The fund will be focused solely on advanced therapies without geographic limit, giving investors undiluted access to the fastest growing field of medicine.
Since 2010 the Group and its founders have participated in 29 biotech investments across the advanced therapies sector, and 4BIO’s investment strategy has been validated by a number of recent exits including Orchard Therapeutics , Seres Therapeutics and RetroSense Therapeutics, acquired by Allergan in 2016.

 


COMMENTS ARE OFF THIS POST